Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Tai-Sung Lee, Steven Potts, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2917.

https://doi.org/10.1182/blood.V110.11.2917.2917

Published: 2007

Journal Articles

Proteasome Chymotrypsin-Like Activity in Plasma Is a Major Predictor of Outcome in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Normal Karyotype.

Wanlong Ma, Iman Jilani, Ph.D., Benjamin Bekele, Hagop Kantarjian, M.D., Amber Donahue, Ph.D., Xi Zhang, Zhong Zhang, M.D., Susan O’Brien, M.D., Elihu Estey, M.D., Zeev Estrov, M.D., Jorge Cortes, M.D., Michael Keating, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2837.

https://doi.org/10.1182/blood.V110.11.2837.2837

Published: 2007

Journal Articles

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.

Richard Tseng, PhD, Chen-Hsiung Yeh, Ph.D., Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Alison Hannah, Ph.D., Zeev Estrov, M.D., Michael Keating, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2922.

https://doi.org/10.1182/blood.V110.11.2922.2922

Published: 2007

Journal Articles

Detection of Nucleophosmin Gene Mutations in Plasma from Patients with Acute Myeloid Leukemia: Clinical Significance and Implications.

Wanlong Ma, Xi Zhang, Iman Jilani, Ph.D., Farhad Ravandi, Elihu Estey, M.D., Hagop Kantarjian, M.D., Francis Giles, M.D., Mohammad Sheikholeslami, M.D., Michael Keating, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2855.

https://doi.org/10.1182/blood.V110.11.2855.2855

Published: 2007

Journal Articles

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Wanlong Ma, Xi Zhang, Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Francis Giles, M.D., Susan O’Brien, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2554.

https://doi.org/10.1182/blood.V110.11.2554.2554

Published: 2007

Journal Articles

Correlation of New Method for Measuring Plasma Myeloperoxidase with Clinical Behavior in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Adam Abdool, Xiugiang Wang, Iman Jilani, Ph.D., Weidong Zhou, M.D., Hagop Kantargian, M.D., Elihu Estey, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4321.

https://doi.org/10.1182/blood.V110.11.4321.4321

Published: 2007

Journal Articles

Higher Sensitivity and Detection of Homozygous/Hemizygous State of JAK2 Mutation Using Plasma.

Wanlong Ma, Xi Zhang, Weimin Sun, Ph.D, Joyce Schwartz, M.D., Arlene Buller, Ph.D., Iman Jilani, Ph.D., Hagop Kantarjian, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4663.

https://doi.org/10.1182/blood.V110.11.4663.4663

Published: 2007

Journal Articles

Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.

Wanlong Ma, Hagop Kantarjian, M.D., Amber Donahue, Ph.D., Xi Zhang, Susan O’Brien, M.D., Iman Jilani, Ph.D., Elihu Estey, M.D., Zeev Estrov, M.D., Jorge Cortes, M.D., Michael Keating, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4546.

https://doi.org/10.1182/blood.V110.11.4546.4546

Published: 2007

Journal Articles

Translational In Vivo and In Vitro Studies in Patients (pts) with Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) and Myeloproliferative Disease (MPD) Treated with MK-0457 (MK), a Novel Aurora Kinase, Flt3, JAK2, and Bcr-Abl Inhibitor.

Raoul Tibes, MD, Francis Giles, M.D., Teresa McQueen, Donald A. Bergstrom, M.D., Ph.D., Steven J. Freedman, M.D., Ph.D., Michael Andreeff, M.D., Ph.D.

Blood (2006) 108 (11): 1362.

https://doi.org/10.1182/blood.V108.11.1362.1362

Published: 2006

Journal Articles

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Taghi Manshouri, PhD, Zeev Estrov, M.D., Alfonso Quintas-Cardama, M.D., Jorge Cortes, M.D., Francis Giles, M.D., David Harris, MS, Waldemar Priebe, PhD;MS, Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD.

Blood (2006) 108 (11): 4885.

https://doi.org/10.1182/blood.V108.11.4885.4885

Published: 2006

Journal Articles

Epidermal Growth Factor Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

Zhong Zhang, MD, Susan O’Brien, M.D., Michael Keating, M.D., Iman Jilani, PhD, Hagop Kantarjian, M.D., Zeev Estrov, M.D., Alessandra Ferrajoli, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2006) 108 (11): 4952.

https://doi.org/10.1182/blood.V108.11.4952.4952

Published: 2006

Journal Articles

A Phase II Study of Oral Interferon-Alpha (IFN-a) for Patients with Essential Thrombocythemia or Polycythemia Vera.

Alfonso Quintas-Cardama, MD, Francis Giles, M.D., Jorge Cortes, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4880.

https://doi.org/10.1182/blood.V108.11.4880.4880

Published: 2006

Journal Articles

Denileukin Diftitox (Ontak™) Therapy for Patients with Systemic Mastocytosis.

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4881.

https://doi.org/10.1182/blood.V108.11.4881.4881

Published: 2006

Journal Articles

The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-α-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.

Jingpan Pan, MD, PhD, Alfonso Quintas-Cardama, M.D., Hagop Kantarjian, M.D., Peter Lamb, Ayalew Tefferi, Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4882.

https://doi.org/10.1182/blood.V108.11.4882.4882

Published: 2006

Journal Articles

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Mary Ann Richie, R.N., Gautam Borthakur, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4884.

https://doi.org/10.1182/blood.V108.11.4884.4884

Published: 2006

Journal Articles

Clinical Significance of Free Circulating CD33 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Menna Hodge, Francis Giles, M.D., Adam Abdool, Susan O’Brien, M.D., Michael Keating, M.D., Iman Jilani, PhD, Zeev Estrov, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Maher Albitar, M.D.

Blood (2006) 108 (11): 4502.

https://doi.org/10.1182/blood.V108.11.4502.4502

Published: 2006

Journal Articles

Comparison of Survival Times after Administration of Tipifarnib or Ara-C-Containing Therapy, to Older Patients with Newly-Diagnosed Acute Myeloid Leukemia.

Elihu H. Estey, MD, Peter F. Thall, Ph.D., X.-M. Wang, M.S., Francis Giles, M.D., Judith E. Karp, M.D.

Blood (2006) 108 (11): 4552.

https://doi.org/10.1182/blood.V108.11.4552.4552

Published: 2006

Journal Articles

Measurement and Clinical Relevance of Proteasome Enzymatic Activity in Plasma of Patients with Acute Lymphoblastic Leukemia.

Wanlong Ma, Hagop Kantarjian, M.D., Susan O’Brien, M.D., Iman Jilani, PhD, Xi Zhang, M.D., Zeev Zestrov, M.D., Elihu Estey, M.D, Alessandra Ferrajoli, M.D., Michael Keating, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2006) 108 (11): 4475.

https://doi.org/10.1182/blood.V108.11.4475.4475

Published: 2006

Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 3636.

https://doi.org/10.1182/blood.V108.11.3636.3636

Published: 2006

Journal Articles

Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age ≥ 60 with Newly-Diagnosed AML.

Elihu H. Estey, MD, Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Hagop M. Kantarjian, M.D.

Blood (2006) 108 (11): 1965.

https://doi.org/10.1182/blood.V108.11.1965.1965

Published: 2006

NARROW

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Proteasome Chymotrypsin-Like Activity in Plasma Is a Major Predictor of Outcome in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Normal Karyotype.

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.

Detection of Nucleophosmin Gene Mutations in Plasma from Patients with Acute Myeloid Leukemia: Clinical Significance and Implications.

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Correlation of New Method for Measuring Plasma Myeloperoxidase with Clinical Behavior in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Higher Sensitivity and Detection of Homozygous/Hemizygous State of JAK2 Mutation Using Plasma.

Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.

Translational In Vivo and In Vitro Studies in Patients (pts) with Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) and Myeloproliferative Disease (MPD) Treated with MK-0457 (MK), a Novel Aurora Kinase, Flt3, JAK2, and Bcr-Abl Inhibitor.

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Epidermal Growth Factor Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

A Phase II Study of Oral Interferon-Alpha (IFN-a) for Patients with Essential Thrombocythemia or Polycythemia Vera.

Denileukin Diftitox (Ontak™) Therapy for Patients with Systemic Mastocytosis.

The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-α-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

Clinical Significance of Free Circulating CD33 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Comparison of Survival Times after Administration of Tipifarnib or Ara-C-Containing Therapy, to Older Patients with Newly-Diagnosed Acute Myeloid Leukemia.

Measurement and Clinical Relevance of Proteasome Enzymatic Activity in Plasma of Patients with Acute Lymphoblastic Leukemia.

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age ≥ 60 with Newly-Diagnosed AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only